Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | CA12 | O43570 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | NR2E3 | Q9Y5X4 | 1/20 | 0.38 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.38 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.38 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14277891 | 0.75 | MEN1 (0.40) | KMT2AMEN1L3MBTL1TDP1HRH3 | |
| SCHEMBL14264173 | 0.72 | MAPT (0.41) | KMT2AMEN1MAPTALDH1A1LMNA | |
| SCHEMBL13799210 | 0.72 | KCNA3 (0.33) | MAPTALDH1A1 | |
| SCHEMBL13799208 | 0.70 | HTR1A (0.50) | DRD4 | |
| SCHEMBL13799206 | 0.68 | PARP1 (0.46) | KMT2AMEN1DRD4MAPTALDH1A1 | |
| SCHEMBL13799234 | 0.67 | ALDH1A1 (0.32) | MAPTALDH1A1 | |
| SCHEMBL16054847 | 0.66 | L3MBTL1 (0.61) | KMT2AMEN1L3MBTL1TDP1HRH3 | |
| SCHEMBL2206628 | 0.65 | KDM4E (0.73) | HRH3MAPTALDH1A1LMNAKCNJ1 | |
| SCHEMBL14264177 | 0.65 | TDP1 (0.44) | KMT2AMEN1TDP1MAPTALDH1A1 | |
| SCHEMBL999018 | 0.65 | MAPT (0.43) | KMT2AMEN1CA12CA9MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090149417-A1 | Methods and compositions for the treatment of cancer using benzopyrone-type PARP inhibitors | BIPAR SCIENCES, INC. | 2009-06-11 | — | — | US | disclosed |
| US-20090149417-A1 | Methods and compositions for the treatment of cancer using benzopyrone-type PARP inhibitors | BIPAR SCIENCES, INC. | 2009-06-11 | — | — | US | disclosed |
| US-20080076778-A1 | METHODS FOR DESIGNING PARP INHIBITORS AND USES THEREOF | BIPAR SCIENCES, INC. (US) | 2008-03-27 | — | — | US | disclosed |
| US-20080076778-A1 | METHODS FOR DESIGNING PARP INHIBITORS AND USES THEREOF | BIPAR SCIENCES, INC. (US) | 2008-03-27 | — | — | US | disclosed |
| WO-2008030887-A2 | METHODS FOR DESIGNING PARP INHIBITORS AND USES THEREOF | BIPAR SCIENCES, INC. (US) | 2008-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149417-A1 | Methods and compositions for the treatment of cancer using benzopyrone-type PARP inhibitors | PARP1, PARP2, PARP3 | KMT2A 768/4885MEN1 2495/4885CA12 3869/4885 |
| US-20080076778-A1 | METHODS FOR DESIGNING PARP INHIBITORS AND USES THEREOF | PARP3, PARP1, PARP15 | KMT2A 982/4885MEN1 3631/4885CA12 4654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.